Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Variants & evidence
325 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| AURKA Overexpression1 | ||||||||
| Platinum Compound | Ovarian Serous AdenocarcinomaALIAS | Predictive | B | Supports Resistance | 3 | accepted | EID1650A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P = 0.001; HR 0.14) and platinum therapy resistance … (full text at CIViC) PMID 27209210 · Mignogna et al., 2016 · Open in CIViC | civic |
| BARD1 Mutation1 | ||||||||
| Olaparib | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11209This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| CUL1 Fusion1 | ||||||||
| Mitogen-Activated Protein Kinase Kinase Inhibitor | Ovarian Serous AdenocarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1662One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcri… (full text at CIViC) PMID 26324360 · Grisham et al., 2015 · Open in CIViC | civic |
| BRAF V600E3 | ||||||||
| Dabrafenib + TrametinibCombination | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7454In NCI-MATCH trial, patients with advanced solid tumors, lymphoma or multiple myeloma harboring BRAF V600E mutation were treated with dabrafenib and trametinib. Patients with melanoma, thyroid carcino… (full text at CIViC) | civic |
| Vemurafenib | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID5959The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 4 pati… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC | civic |
| 〃 | Ovarian Serous AdenocarcinomaALIAS | Predictive | C | |||||
| BRAF Amplification + BRAF V600E1 | ||||||||
| Atezolizumab + BevacizumabCombination | Ovarian CarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 1 | submitted | EID9885AURELIA trial indicated substantial improvement in progression-free survival and overall survival in ovarian cancer patients with PD-L1 positive expression in response to bevacizumab plus single regim… (full text at CIViC) PMID 31105696 · Zhang et al., 2019 · Open in CIViC | civic |
| BRAF Wildtype1 | ||||||||
| Cetuximab | Malignant Ovarian Neoplasm | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID11663In a clinical study of 49 patients, 29 patients with Ovarian Cancer and wild-type BRAF gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of 8 weeks (95% CI, 6.… (full text at CIViC) PMID 33090333 · Fisher et al., 2020 · Open in CIViC | civic |
| BRCA1 ATM1 | ||||||||
| Olaparib | Malignant Prostate Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | rejected | EID7456In a retrospective study, 23 consecutive patients with prostate cancer harboring germline BRCA1/2 or ATM mutations were treated with olaparib were reviewed. This study included 2 patients with BRCA1 m… (full text at CIViC) PMID 30797618 · Marshall et al., 2019 · Open in CIViC | civic |
| BRCA1 c.212+1G>T1 | ||||||||
| (predisposing) | Malignant Prostate Neoplasm | Predisposing | C | Supports Predisposition | 3 | submitted | EID7164Mutation disrupts the splice donor site, allowing read-through into the intron and termination of transcription at codon 64 Located in N-terminus RING finger domain, which is highly conserved. 57 year… (full text at CIViC) PMID 22516946 · Leongamornlert et al., 2012 · Open in CIViC | civic |
| BRCA1 Loss-of-function4 | ||||||||
| (prognostic) | Malignant Prostate Neoplasm | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1523In a study of 2,019 patients with prostate cancer, 18 had germline BRCA1 mutations, 61 had germline BRCA2 mutations and 1,940 were non-carriers. Patients with BRCA1/2 mutations had a 2-fold higher in… (full text at CIViC) PMID 23569316 · Castro et al., 2013 · Open in CIViC | civic |
| Olaparib | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID211The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undi… (full text at CIViC) PMID 23346317 · Goff, 2013 · Open in CIViC | civic |
| 〃 | Malignant Prostate Neoplasm | Predictive | C | Supports Sensitivity Response | ||||
| BRCA1 Mutation20 | ||||||||
| (prognostic) | Ovarian CarcinomaALIAS | Prognostic | B | Supports Better Outcome | 3 | accepted | EID464In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival. PMID 22274685 · Bolton et al., 2012 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1675664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo. Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and … (full text at CIViC) PMID 26740259 · Harter et al., 2016 · Open in CIViC | civic |
| Olaparib | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | |||
| BRCA1 Mutation + BRCA2 MutationBRCA2BRCA18 | ||||||||
| Olaparib | Malignant Prostate Neoplasm | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12941In the BRCA‑altered cohort (n = 160; BRCA1/2 alterations) of the global, randomized, open‑label phase III PROfound trial (NCT02987543) in metastatic castration‑resistant prostate cancer (mCRPC), patie… (full text at CIViC) PMID 37963304 · Mateo et al., 2024 · Open in CIViC | civic |
| Rucaparib | Malignant Prostate Neoplasm | Predictive | A | Supports Sensitivity Response | 4 | rejected | EID11245In an open-label, phase 2 study, 115 male patients with castration-resistant prostate cancer and a BRCA1/2 alteration with or without measurable disease were enrolled to receive rucaparib 600 mg twice… (full text at CIViC) PMID 32795228 · Abida et al., 2020 · Open in CIViC | civic |
| Niraparib | Ovarian CarcinomaALIAS | |||||||
| BRCA1 P968FS1 | ||||||||
| (predisposing) | Malignant Ovarian Neoplasm | Predisposing | C | Supports Predisposition | 4 | accepted | EID1124A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 302… (full text at CIViC) PMID 24137399 · Salgado et al., 2013 · Open in CIViC | civic |
| BRCA1 Q1467*1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2878In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA1 Underexpression1 | ||||||||
| Platinum Compound + Taxane CompoundCombination | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID942Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%C… (full text at CIViC) PMID 21920589 · Carser et al., 2011 · Open in CIViC | civic |
| BRCA1 W1815X1 | ||||||||
| Olaparib | Ovarian Endometrioid AdenocarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID4623In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines e… (full text at CIViC) PMID 23415752 · Stordal et al., 2013 · Open in CIViC | civic |
| BRCA2 Loss-of-function4 | ||||||||
| (prognostic) | Malignant Prostate Neoplasm | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1524In a study of 2,019 patients with prostate cancer, 18 had germ-line BRCA1 mutations, 61 had germ-line BRCA2 mutations and 1,940 were non-carriers. Patients with BRCA1/2 mutations had a 2-fold higher … (full text at CIViC) PMID 23569316 · Castro et al., 2013 · Open in CIViC | civic |
| Cisplatin + DasatinibCombination | Malignant Prostate Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID8981Transcriptomic analysis of BRCA2-null metastatic castration-resistant prostate cancers revealed activation of the SRC signaling pathway. Platinum-based chemotherapies have shown efficacy in BRCA2-alte… (full text at CIViC) PMID 33334906 · Chakraborty et al., 2021 · Open in CIViC | civic |
| Dasatinib + TalazoparibCombination | Malignant Prostate Neoplasm | |||||||
Data updated 12 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| 3 |
| accepted |
EID3787A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard ch… (full text at CIViC) PMID 26490654 · Combe et al., 2015 · Open in CIViC |
| civic |
| 2 |
| accepted |
EID8451/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study. PMID 26510020 · Mateo et al., 2015 · Open in CIViC |
| civic |
| Talazoparib | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID4876In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC) PMID 28242752 · de Bono et al., 2017 · Open in CIViC | civic |
EID7274In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC |
| civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | rejected | EID7277In phase 3 trial for patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had coplete or partial response after platinum-based chemotherapy were treated with ola… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC | civic |
| 〃 | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11203This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| 〃 | Malignant Prostate Neoplasm | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12943In the post hoc exploratory BRCA1-only subgroup (n = 13; olaparib, n = 8; control, n = 5) of the phase III randomized open-label PROfound trial (NCT02987543), olaparib monotherapy supported Sensitivit… (full text at CIViC) PMID 37963304 · Mateo et al., 2024 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 1 | accepted | EID7275In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC | civic |
| 〃 | Ovarian Serous AdenocarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID6333In patients with platinum-sensitive, recurrent serous ovarian cancer with BRCA mutation, median PFS was significantly longer in patients that received olaparib as compared to placebo (11.2 vs. 4.3 mon… (full text at CIViC) PMID 24882434 · Ledermann et al., 2014 · Open in CIViC | civic |
| 〃 | Malignant Prostate Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7470In a phase 2 trial, patients with metastatic castration-resistant prostate cancer harboring DNA damage repair (DDR) gene aberrations were treated with olaparib. In gene testing, samples from tumor tis… (full text at CIViC) | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1772In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations. Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective r… (full text at CIViC) PMID 21862407 · Gelmon et al., 2011 · Open in CIViC | civic |
| 〃 | Malignant Prostate Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7459In a retrospective study, 23 consecutive patients with prostate cancer harboring germline BRCA1/2 or ATM mutations were treated with olaparib were reviewed. This study included 2 patients with BRCA1 m… (full text at CIViC) PMID 30797618 · Marshall et al., 2019 · Open in CIViC | civic |
| Cediranib + OlaparibCombination | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID167746 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy. Median PFS was increased in combination therapy (… (full text at CIViC) PMID 25218906 · Liu et al., 2014 · Open in CIViC | civic |
| Platinum Compound | Ovarian Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1529In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC | civic |
| 〃 | Ovarian Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1531In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC | civic |
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11136Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11138Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1897A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID6341A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| 〃 | Castration-Resistant Prostate Carcinoma | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID13266In a prespecified subgroup analysis of the randomized phase III TRITON3 trial, patients with metastatic castration-resistant prostate cancer harboring germline or somatic deleterious BRCA1 alterations… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| Enzalutamide + TalazoparibCombination | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID11734This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC) PMID 38049622 · Fizazi et al., 2024 · Open in CIViC | civic |
| Predictive |
| A |
| Supports Sensitivity Response |
| 4 |
| accepted |
EID11243In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC |
| civic |
| 〃 | Fallopian Tube Carcinoma | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11305In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC | civic |
| Abiraterone + NiraparibCombination | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11738A phase 3 trial (NCT03748641) evaluated the clinical benefit of the PARP inhibitor niraparib in combination with abiraterone acetate plus prednisone (AAP) in metastatic castration-resistant prostate … (full text at CIViC) PMID 36952634 · Chi et al., 2023 · Open in CIViC | civic |
| Olaparib | Malignant Prostate Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID11666A clinical study was conducted in 30 patients with Metastatic Prostate Cancer harboring BRCA1/2 mutations treated with olaparib. A disease control rate of 69% (95% CI, 51-81) and an objective response… (full text at CIViC) PMID 36753688 · Yang et al., 2023 · Open in CIViC | civic |
| 〃 | Malignant Uterine NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID12766In the uterine carcinoma cohort of the phase II TAPUR trial (NCT02693535), PRs were observed in 3 of 15 evaluable patients with BRCA1 (n = 2) or BRCA2 (n = 1) alterations, with response durations of 8… (full text at CIViC) PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC | civic |
| Rucaparib | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID12944In the BRCA-altered cohort (n = 302; deleterious BRCA1/2 alterations) of the global, randomized, open-label phase III TRITON3 trial (NCT02975934) in mCRPC, pts treated with rucaparib (600 mg twice/day… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| Predictive |
| D |
| Supports Sensitivity Response |
| 4 |
| submitted |
EID8980Transcriptomic analysis of BRCA2-null metastatic castration-resistant prostate cancers revealed activation of the SRC signaling pathway, which may be related to PARP inhibitor resistance. Preclinical … (full text at CIViC) PMID 33334906 · Chakraborty et al., 2021 · Open in CIViC |
| civic |
| Olaparib | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID212The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undi… (full text at CIViC) PMID 23346317 · Goff, 2013 · Open in CIViC | civic |